Kern Pharma
↗Terrassa, Spain
Kern Pharma is a prominent Spanish pharmaceutical company and a subsidiary of the Indukern Group. The company focuses on the development, manufacturing, and marketing of a wide range of pharmaceutical products, including generic medicines, biosimilars, hospital products, and over-the-counter (OTC) medications.
Beyond its own product portfolio, Kern Pharma is a significant player in contract manufacturing (CDMO) services, providing chemical production and finished dosage form development for third-party pharmaceutical companies. The company operates its own manufacturing facilities in Terrassa, Spain, and maintains an international commercial presence across Europe, Latin America, and other global markets.
CLASSIFICATION
SIZE & FINANCIALS
Employees:501-1000
Revenue:$50M-$100M
Founded:1999
Ownership:private
Status:operating
FUNDING
Investors:Indukern Group
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Parent Company:Indukern Group
Key Partnerships:Celltrion Healthcare (Commercialization of biosimilars including Remsima, Truxima, Herzuma, and Yuflyma in Spain and Portugal), Reig Jofre (Joint development of injectable anesthetics)
COMPETITION
Position:Niche Player
Competitors:Laboratorios Normon, Teva Pharmaceuticals, Cinfa Biotech
LEADERSHIP
Key Executives:
Silvia Marin - Director Regulatory Affairs
LINKS
Website:kernpharma.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Kern Pharma and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Kern Pharma. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.